secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2026-08-14T20:35:17+00:00
Accession:  0001213900-26-090181
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma Q3 FY26: LYMPHIR revenue $1.5M, net loss $8.9M, cash $17M
-----------------------------------------------------------------------

- Q3 FY26 revenue $1.5M from LYMPHIR (vs $0 prior year); nine-month revenue $7.1M.
- Net loss $8.9M ($0.34/share) for Q3; $38.3M ($1.64/share) for nine months.
- Cash and equivalents $17.0M at June 30, 2026; raised $4.5M offering, $9.7M warrants, $10M loan.
- LYMPHIR now at 44 institutions; institutional vial orders up 31%, new institutions up 80%; July orders 383 vials.
- G&A includes $19.7M non-recurring contract cancellation charge in March 2026; commercial team expanded to 29.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026090181/0001213900-26-090181-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026090181/ea0302227-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-090181

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer